Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837580 | 1.00 | TSHR (0.47) | TSHRTACR1KDM4EPOLBCA1 | |
| SCHEMBL31450118 | 1.00 | TSHR (0.47) | TSHRTACR1KDM4EPOLBCA1 | |
| SCHEMBL25212600 | 1.00 | TSHR (0.47) | TSHRTACR1KDM4EPOLBCA1 | |
| SCHEMBL29345920 | 0.85 | TSHR (0.45) | TSHRTACR1KDM4EPOLB | |
| SCHEMBL21332833 | 0.82 | TSHR (0.42) | TSHRTACR1KDM4EPOLBCA1 | |
| SCHEMBL25240765 | 0.81 | TSHR (0.41) | TSHRTACR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL31387728 | 0.81 | TSHR (0.41) | TSHRTACR1KDM4ESLC6A4 | |
| SCHEMBL25240763 | 0.81 | TSHR (0.41) | TSHRTACR1SLC6A2SLC6A4OPRM1 | |
| SCHEMBL30959565 | 0.81 | TSHR (0.41) | TSHRTACR1SLC6A4 | |
| SCHEMBL25268260 | 0.77 | CA2 (0.38) | TSHRTACR1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC | 2026-03-26 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4577214-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019819-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| US-20240417408-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| EP-4436571-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2024051763-A1 | QUINAZOLINE HETEROCYCLIC DERIVATIVE OF KRAS MUTATION INHIBITOR FOR TREATING CANCER | 深圳福沃药业有限公司 | 2024-03-14 | — | — | WO | disclosed |
| CN-117659050-A | Quinazoline heterocyclic derivatives as KRAS mutation inhibitors for the treatment of cancer | 深圳福沃药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044667-A2 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023097227-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | MERCK SHARP & DOHME LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022250170-A9 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022251576-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022250170-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317759-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | KRAS, NRAS, HRAS | TSHR 4500/4885TACR1 4021/4885KDM4E 3080/4885 |
| US-20240417408-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | TSHR 4589/4885TACR1 4196/4885KDM4E 3014/4885 |
| US-20260083750-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | KRAS, NRAS, RASGRP1 | TSHR 4374/4885TACR1 4185/4885KDM4E 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.